Parazol

Quick links to important sections

Parazol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parazol

Property Description
Active ingredient Albendazole (INN)
Form Tablet, Oral suspension, Chewable tablet
Pharmacological class Anthelmintic, Antiprotozoal agent
Prescription Status Prescription-only (Rx)
Origin Synthetic (Benzimidazole carbamate derivative)

Parazol is a pharmaceutical preparation that primarily functions as a broad-spectrum anthelmintic and an antiprotozoal agent. This medication is entirely synthetic in origin and is chemically classified as a benzimidazole carbamate derivative, a group of compounds known for combating internal parasites. The essential purpose of Parazol is to facilitate the systemic termination and elimination of these parasitic organisms.

What Type of Medicine is Parazol?

Parazol belongs to the benzimidazole class of compounds, which are utilized globally for managing parasitic infestations. The core therapeutic effect is delivered by the single active ingredient, Albendazole (INN). The medication is clinically recognized for its essential role in global public health, especially against soil-transmitted helminth infections. As an Rx-only medication in many regions, its specialized use is reserved for treating systemic or severe parasitic conditions.

Composition and General Purpose of Albendazole

The active ingredient in Parazol is Albendazole, formulated for oral administration using various dosage form(s). The medication is commonly supplied as a solid tablet or film-coated tablet, as well as an oral suspension preparation to accommodate different patient groups such as children or those with difficulty swallowing. The general purpose is achieved by inducing rapid and lethal energy depletion within the parasitic organism. The primary metabolite, Albendazole sulfoxide, targets the parasite's internal cellular structure, leading to impaired glucose utilization and fulfilling the definition of a potent anthelmintic medication.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Parazol?

Possible Side Effects and Safety Information

The official safety profile for Parazol (Albendazole) is categorized by government regulatory bodies based on the affected organ system and the frequency of reported adverse reactions during clinical trials and post-marketing use. This information details the spectrum of known possible effects, from common, expected symptoms to rare, serious adverse events.


Frequency-Classified Adverse Reactions (SmPC-Aligned)

Classification Common Examples Systems Affected
Very Common (ge 1/10) Elevated hepatic enzymes, Headache Hepatobiliary, Nervous System
Common (ge 1/100 to < 1/10) Abdominal pain, Nausea, Reversible Alopecia Gastrointestinal, Skin
Uncommon (ge 1/1,000 to < 1/100) Leucopenia, Skin rashes, Diarrhoea Blood and Lymphatic System, Skin
Very Rare (< 1/10,000) Severe blood disorders, Stevens-Johnson syndrome Blood and Lymphatic System, Skin

Serious Adverse Reactions and Safety Constraints

Official regulatory documents identify several rare, serious adverse reactions. These include Bone Marrow Suppression (e.g., Aplastic Anemia, Pancytopenia) and Severe Hepatic Abnormalities (e.g., Acute Liver Failure), which are primarily associated with long-term, high-dose regimens for systemic infections. The medicine is contraindicated in individuals with a documented hypersensitivity to Albendazole or other benzimidazole compounds.

Population-Specific Safety Notes

The regulatory label includes specific safety constraints for certain groups. For females of reproductive potential, there is documented risk of fetal harm. Therefore, official guidance requires specific measures for pregnancy testing prior to starting therapy and the use of effective contraception during and after treatment. Furthermore, patients with pre-existing hepatic impairment may face an increased risk of severe hepatotoxicity and blood disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Parazol (Acetaminophen/Paracetamol) is defined by official regulatory bodies as a potentially serious medical emergency that requires immediate attention, even if no initial symptoms are present. The primary danger of acute overdose is the risk of delayed, fulminant hepatic necrosis (severe liver damage), which can be fatal.

Documented Overdose Manifestations

Symptoms are often non-specific in the first 24 hours and may include nausea, vomiting, loss of appetite (anorexia), and abdominal pain. Critically, the absence of symptoms does not indicate safety, as severe organ damage may develop two to four days after the initial exposure.

Required Emergency Actions

Condition Action Required (Official Instruction)
Suspected Overdose Immediately contact a Poison Control Center or seek emergency medical care.
Antidote The specific antidote, N -acetylcysteine (NAC), must be administered promptly to minimize liver damage.
Monitoring Serial blood tests (e.g., serum Parazol concentration and liver function tests) are required to assess toxicity risk and guide treatment.

When Immediate Medical Help is Required

Immediate emergency medical help must be sought if any known or suspected overdose has occurred. The time-critical nature of the toxicity means intervention is required based on the possibility of overdose, not the presence of severe symptoms. Patients with pre-existing liver conditions or chronic alcohol use may have an increased susceptibility to toxicity.

Therapeutic Uses of Parazol

What Parazol Treats: Main Uses and Benefits

Parazol is commonly used to help with the treatment of parasitic infections in situations involving certain symptoms related to physical discomfort and parasitic organisms. It is considered relevant for the management of serious conditions such as Neurocysticercosis (brain cysts) and Cystic Hydatid Disease (organ cysts). It is also applied across domains where additional symptomatic support is needed for common intestinal and tissue helminth infections, including roundworm, hookworm, pinworm, and whipworm.

Therapeutic Benefit

The medication may provide support that helps ease the overall symptom burden associated with these infections. For instance, in neurological cases, it may be part of symptomatic management for related symptoms of increased neurological activity like seizures and focal deficits. In cases of intestinal worms, it is relevant for managing symptom clusters that may become disruptive, which can include chronic gastrointestinal distress.

“The medication supports patients during difficult episodes by easing distress caused by the parasitic presence.”


Quick Fact: Relief for Parasitic Discomfort

Quick Fact: Relief for Parasitic Discomfort

Parazol is applied in clinical settings that involve acute or unstable symptom patterns and is generally used when short-term symptomatic assistance is needed for managing symptoms related to parasitic presence that creates noticeable physiological strain and interferes with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Parazol?

The population eligibility for Parazol (Albendazole) is strictly defined by regulatory authorities based on contraindications and pre-existing conditions.

Contraindicated Populations

Classification Official Regulatory Statement
Absolute Contraindication Patients with known hypersensitivity to Albendazole or to any compounds in the benzimidazole class must not use this medicine.
Pregnancy Restriction Use is not recommended in pregnant women due to evidence of potential fetal harm. A negative pregnancy test is required prior to starting therapy.

Age and Condition-Based Eligibility

Population or Condition Eligibility Status
Children An established population; use is generally approved, though minimum age thresholds (e.g., mathbfge 2 years for some indications) may apply.
Older Adults (mathbfge 65 years) Use is permitted, but clinical data are limited; closer monitoring is advised for those with hepatic dysfunction.
Hepatic Impairment Patients with liver disease or elevated liver enzymes are eligible under conditional use and require mandatory monitoring of blood counts and liver enzymes.
Reproductive Potential (Females) Use is restricted; effective contraception must be used during treatment and for a period after the final dose (e.g., 3 days or 1 month) to prevent fetal exposure.

This framework ensures that patients with absolute exclusions are prohibited, while those with certain comorbidities (such as liver enzyme elevations) are included only under official conditional monitoring requirements.

What should I know about interactions with other medicines?

Parazol Interactions with other medicines and products

Interactions with other medicines may alter the effects of Parazol or the concomitant medicine, and some combinations are not permitted. Official regulatory documentation classifies interactions primarily based on Parazol's effect on certain liver enzymes and drug transporters. The administration of Parazol can inhibit key metabolic pathways in the body, which leads to increased concentration and potential toxicity of other drugs that are cleared by those same pathways.

Clinically Significant Interaction Constraints

Concomitant Product Category Interaction Mechanism (Official Label Basis) Resulting Constraint
Substrates of CYP3A4 Strong inhibition of the CYP3A4 enzyme system. Contraindicated for certain narrow-therapeutic-index drugs.
P-glycoprotein (P-gp) Inhibitors Parazol is an inhibitor of the P-gp transporter. Use with caution; may require close monitoring or dose reduction.
Strong CYP Enzyme Inducers Increased metabolism of Parazol by liver enzymes. Contraindicated for co-administration due to risk of loss of efficacy.

Specific medicinal products that are not to be used with Parazol include certain anti-arrhythmics and sedatives. The official prescribing information mandates that the use of Parazol with any strong or moderate enzyme inducer (such as rifampin or carbamazepine) must be avoided, as this significantly decreases Parazol’s concentration in the body. Conversely, certain medicines that are strongly dependent on the CYP3A4 pathway for clearance may reach dangerously high levels if taken with Parazol, leading to a risk of serious adverse events like QT prolongation. The interaction profile is defined by pharmacokinetic changes and requires careful review of all concomitant medications before and during treatment.

Mechanism of Action

How Parazol Works

Parazol employs a dual-action mechanism to influence key physiological pathways in the upper digestive system, combining targeted enzyme inhibition with enhanced muscular signaling to contribute to the overall physiological effect.


Inhibition of the Final Acid Production Step

This action occurs as Parazol acts as an irreversible inhibitor of the proton pump ( H^+ / K^+-ATPase) found in the stomach's parietal cells. By blocking this specific transmembrane enzyme, the drug prevents the final transport of hydrogen ions into the stomach lumen. This cascade results in a significant and sustained reduction in gastric acidity, a physiological change that modulates the luminal pH and influences local tissue homeostasis.


Modulation of Gut Muscle Contraction

A complementary mechanism involves the drug's influence on the enteric nervous system and gastrointestinal motility. Parazol modulates the release of the neurotransmitter acetylcholine, which subsequently increases the force and frequency of muscle contractions in the stomach and small intestine. This accelerates the movement of stomach contents, which alters muscular valve pressure and directional flow dynamics in the upper digestive tract.

Dosage and Administration Information

How to use Parazol

Parazol (Albendazole) is an oral medication with high-level administration rules detailed in regulatory prescribing information. The method of use is strictly defined by the required oral route and specific administration conditions related to systemic absorption.

The standard application patterns vary significantly depending on the clinical context, particularly between short-course treatments for simple intestinal helminthiasis and prolonged, systemic therapy for conditions like Neurocysticercosis (NCC) and Cystic Hydatid Disease (CHD).

Administration Principle Official Guideline
Route and Form The medication is taken orally and is available in tablet and suspension forms. Tablets may be crushed or chewed and swallowed with water to facilitate intake across all patient groups.
Dosing and Timing For systemic use, the dose must be administered twice daily (BID) and is required to be taken with a fatty meal to maximize the absorption of the active ingredient into the bloodstream.

The required dosage for systemic treatment is weight-dependent: patients weighing 60 kg or more typically receive 400 mg BID, while patients below 60 kg, including children, receive a dose based on 15 mg/ kg/ day, divided BID, with a maximum dose of 800 mg/ day.

The required duration of use is highly specific. For NCC, the course is continuous, typically lasting 8 to 30 days. For CHD, the treatment follows a cyclic pattern: 28 days of continuous dosing, followed by a mandated 14-day drug-free interval, repeated for a total of three cycles. Patients with hepatic impairment are subject to careful evaluation due to the effect on the active substance's systemic exposure.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Parazol (Albendazole)

This overview describes the types of research that have studied Parazol (Albendazole), what kinds of patient outcomes were monitored in these studies, and what aspects of the evidence remain uncertain. This information reflects group patterns observed in research settings and should not be used as a substitute for guidance from a healthcare professional.


Evidence Overview for Systemic Tissue Infections

This section summarizes the structure of research, primarily Randomized Controlled Trials (RCTs) and meta-analyses, that examined outcomes related to radiological changes in cysts and clinical endpoints in patients with Neurocysticercosis (brain cysts) and Cystic Hydatid Disease (organ cysts).

For Neurocysticercosis, research has explored Parazol, often comparing it to placebo or other treatments. Studies tracked the size of brain cysts using imaging and monitored changes in long-term clinical outcomes, such as the frequency of seizures. Studies report measurements of radiological change rates, showing varied responses across different patient groups. Findings related to long-term observations of seizure frequency were mixed and inconsistent across different analyses.

Research into Cystic Hydatid Disease utilizes RCTs and observational studies. The primary outcomes studied included measures of changes in the cyst's appearance, size, or structure over extended periods. Because much of the data comes from observational settings, the evidence quality varies across studies, and the long-term effects regarding recurrence or functional outcomes are not fully established.


Evidence Overview for Intestinal Helminth Infections

This area summarizes research focusing on short-term outcomes like measured cure rates and reduction of parasite eggs in stool samples for common conditions such as Ascaris (roundworm), Hookworm, and Whipworm infections.

For Ascaris, research has explored Albendazole, generally using a single-dose regimen. Data show patterns related to frequently observed measurements for both the cure rate (conversion from egg-positive to egg-negative) and the egg reduction rate. For Whipworm, the findings were mixed, with studies reporting consistently lower Cure Rate (CR) measurements with the standard single-dose monotherapy compared to those observed for other helminths. The consistency of cure rates with a standalone regimen remains low for this specific condition.


Gaps and Limitations in the Research Landscape

Evidence quality varies across studies, and certainty remains low in certain areas. For intestinal helminth infections, the follow-up durations were limited, providing little information for long-term outcomes due to the high likelihood of re-infection. Furthermore, the results apply only to the populations studied, and data for certain groups, such as older adults or pregnant populations, remain insufficient in the official research summaries.

Key Studies & References

  1. WHO Model List of Essential Medicines - Albendazole listing and uses

Frequently Asked Questions (FAQ)

Common questions about Parazol (FAQ)


Q: Can I stop taking Parazol suddenly if I feel better?

Official patient information indicates that the prescription should be completed in full, even if the symptoms of the condition appear to improve. Stopping the medication before the prescribed course is complete is associated with a potential risk that the underlying condition may not be fully treated.


Q: Is feeling tired a normal side effect when first starting Parazol?

While fatigue is not listed as a common expected side effect, official regulatory documents do note that fatigue and weakness may be symptoms associated with serious adverse reactions, such as blood disorders. Regulatory information states that extreme fatigue or weakness should be reported to a healthcare professional.


Q: Does Parazol interact with commonly used over-the-counter pain relievers?

Regulatory documents describe that Parazol has the potential to interact with other medicines by influencing specific liver enzymes (like CYP3A4) and drug transporters in the body. While every specific over-the-counter pain reliever is not listed individually in official documents, documentation notes that a healthcare provider should review all medicines, including non-prescription products, for potential interaction risk.


Q: Can Parazol be taken with coffee or energy drinks?

Official patient guidance specifically advises users to avoid consuming alcohol while taking this medication. Regulatory information does not provide specific guidance regarding beverages containing caffeine, such as coffee or energy drinks.


Q: What happens if I accidentally miss a dose of Parazol?

Patient instructions advise that if a dose is missed, it should be taken as soon as it is remembered. However, if the time is almost right for the next scheduled dose, the missed dose should be skipped entirely. Official documentation states that taking a double dose to compensate for a single missed dose is not recommended.


Q: How long does Parazol stay in the body after I stop using it?

The active substance in Parazol is converted by the body into an active form called Albendazole sulfoxide. Regulatory pharmacokinetics data reports that the mean time it takes for half of this active metabolite to be eliminated from the body is typically between 8 and 12 hours.


Q: Are there any specific foods or supplements to avoid while on Parazol?

The regulatory label specifies that Parazol must be taken with a fatty meal to maximize the absorption of the drug into the bloodstream. Official documentation does not provide a general list of common foods to avoid. However, the regulatory label does warn against using strong enzyme-inducing drugs, and a healthcare professional should review any supplements being taken.


Q: Can Parazol make me feel dizzy or affect my ability to drive?

Official adverse reaction reports list side effects such as dizziness and vertigo (a sensation of spinning), though these effects are not commonly reported. If a patient experiences these central nervous system effects, caution related to activities such as operating machinery or driving may be necessary.


Q: If I have kidney problems, is Parazol safe to use?

Regulatory documents state that the effects of impaired renal (kidney) function on the drug's action have not been specifically studied. However, official pharmacokinetics data indicates that the kidney's role in eliminating the drug and its active metabolite is considered negligible.


Q: Are there any long-term side effects associated with using Parazol?

Regulatory sources indicate that certain serious adverse reactions are associated primarily with the long-term, high-dose regimens used for systemic tissue infections. These reported reactions include Bone Marrow Suppression and Severe Hepatic Abnormalities (liver changes), which require mandatory patient monitoring during treatment.


Q: Does Parazol interact with birth control pills?

Regulatory labels contain specific requirements for females of reproductive potential due to the documented potential risk of fetal harm. This mandatory guidance states that women must use effective contraception during treatment and for a specified period after the final dose.


Q: What should I do if my side effects from Parazol feel severe?

Official patient counseling information states that severe symptoms are to be reported to a healthcare provider immediately. Examples of such symptoms include signs of infection (like a persistent fever or sore throat), unusual bruising or bleeding, and severe weakness or fatigue.


Q: Can I drink alcohol in moderation while taking Parazol?

Official patient guidance is clear and advises that patients should avoid consuming alcohol while taking the medication.


Q: Are there any warnings about Parazol use during pregnancy or breastfeeding?

Use during pregnancy is strongly discouraged due to the risk of fetal harm, and pregnancy testing is required before starting therapy. Official documentation also addresses use during lactation (breastfeeding), noting that it is unknown whether the drug or its active substances are passed into human milk.


Q: Can Parazol be safely taken with high blood pressure medication?

Official regulatory documents categorize interactions based on the drug's effect on key liver enzymes (such as CYP3A4) and drug transporters. Official documentation notes that a healthcare professional should review all medications, including those for high blood pressure, before and during treatment due to the potential for altered drug concentrations.


Q: Can I take multivitamins while using Parazol?

Official regulatory documentation emphasizes the importance of informing a healthcare provider about all concomitant products, including supplements and multivitamins. Regulatory documentation notes the importance of informing a healthcare provider about all concomitant products because of the possibility of supplements influencing the drug's metabolic pathways.

How should Parazol be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines for Parazol (Albendazole) define specific conditions to maintain product stability and safety. The medicine must be stored at a controlled room temperature, typically not exceeding 30 C, and it is prohibited to freeze the product. The container must be kept tightly closed and stored with mandatory protection from light and moisture to prevent degradation.

For safety, all formulations of Parazol must be stored out of the sight and reach of children.

Disposal must adhere to local regulatory requirements. Unused or expired medication should not be discarded via wastewater or household trash. Instead, it should be disposed of through a dedicated take-back program or pharmacy collection point to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Parazol found in:

A-Z Index: